113
Participants
Start Date
August 15, 2015
Primary Completion Date
May 9, 2016
Study Completion Date
July 15, 2016
MEDI9929
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
Placebo
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
Research Site, Liverpool
Research Site, Tauranga
Research Site, Miskolc
Research Site, Debrecen
Research Site, Wellington
Research Site, Szeged
Research Site, Kaposvár
Research Site, Pécs
Research Site, Szombathely
Research Site, Berlin
Research Site, Charlotte
Research Site, Hanover
Research Site, North Miami Beach
Research Site, Tampa
Research Site, Carmel
Research Site, Indianapolis
Research Site, Münster
Research Site, Arlington Hts
Research Site, Frankfurt am Main
Research Site, München
Research Site, Portland
Research Site, Berlin
Research Site, ACT
Research Site, Woolloongabba
Research Site, Surrey
Research Site, Barrie
Research Site, Québec
Research Site, Gera
Research Site, Leipzig
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
MedImmune LLC
INDUSTRY